ALK represents an attractive target for innovative combination therapies based on selective small-molecule inhibitors of its tyrosine kinase activity or on its use as an oncoantigen for tumour ...

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Dose response curves for cells treated with ALK inhibitors crizotinib and ceritinib (Figure 3 A, B) showed that the isogenic A549 EML4-ALK cell line has selective drug sensitivity to ALK ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Ensartinib doubled median progression-free survival (PFS) over the first-generation ALK inhibitor, with a median PFS of 25.8 months versus 12.7 months, respectively (HR 0.56, 95% CI 0.40-o.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

The company also has NVL-655, an ALK-selective inhibitor for ALK-driven NSCLC. Similar to Zidesamtinib, NLV-655 has brain penetrance, so it should minimize the negative effects on the CNS ...

Myelodysplastic syndromes (MDS) are marked by ineffective hematopoiesis and dysplasia, which elevate the risk of progression to acute myeloid leukemia (AML). The inflammatory environment in MDS alters ...

in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Report pivotal data for tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small ...